USPTO Grants Patent on Opsens Technology

Opsens Inc. has announced today that the United States Patent and Trademark Office (USPTO) has granted Opsens, patent no. 7,259,862 entitled Low-coherence interferometry optical sensor using a single wedge polarization readout interferometer.

This patent protects Opsens' white-light polarization interferometric (WLPI) technology.

The WLPI technology is the results of three years of extensive research and development and its outcome is a complete line of fiber optic sensors and signal conditioners for measuring various physical parameters such as pressure, temperature, strain and displacement. This unique technology is highly competitive amongst other sensing technologies when it comes to measurement applications in the harshest environments. The WLPI technology is used by Opsens in various markets such as oil and gas and medical industries.

"This patent award represents an important milestone for the development of our strategic markets such as the medical and the oil and gas markets. Our awarded patent has very broad and fundamental claims, and we are pleased with this recognition of the WLPI technology by the USPTO. Opsens has also other pending patent applications for the WLPI technology in various countries to protect its worldwide commercialization plan." said Gaétan Duplain, Vice President Energy at Opsens and the patent's inventor.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.